ASX:DVL

dorsaVi Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

dorsaVi (ASX:DVL) Vs. BUX, IME, BD1, CRL, CTE, and EPGNY

Should you be buying DVL stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to dorsaVi, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and Epigenomics (EPGNY).

dorsaVi (ASX:DVL) and (BUX) (CNSX:BUX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares dorsaVi and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
(BUX)N/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for dorsaVi and (BUX), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
(BUX)0000N/A

Valuation and Earnings

This table compares dorsaVi and (BUX)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
(BUX)N/AN/AN/AN/AN/A

(BUX) has lower revenue, but higher earnings than dorsaVi.

Summary

dorsaVi beats (BUX) on 1 of the 1 factors compared between the two stocks.

dorsaVi (ASX:DVL) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for dorsaVi and 12144, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
121440000N/A

Profitability

This table compares dorsaVi and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
12144N/AN/AN/A

Earnings and Valuation

This table compares dorsaVi and 12144's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00C$-3,158,396.93A($0.01)N/A
12144N/AN/AN/AN/AN/A

12144 has lower revenue, but higher earnings than dorsaVi.

Summary

dorsaVi beats 12144 on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares BARD1 Life Sciences and dorsaVi's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A

dorsaVi has higher revenue and earnings than BARD1 Life Sciences.

Analyst Ratings

This is a summary of recent recommendations for BARD1 Life Sciences and dorsaVi, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BARD1 Life Sciences0000N/A
dorsaVi0000N/A

Profitability

This table compares BARD1 Life Sciences and dorsaVi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BARD1 Life SciencesN/AN/AN/A
dorsaViN/AN/AN/A

Summary

dorsaVi beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares Charles River Laboratories International and dorsaVi's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A

Charles River Laboratories International has higher earnings, but lower revenue than dorsaVi.

Profitability

This table compares Charles River Laboratories International and dorsaVi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
dorsaViN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Charles River Laboratories International and dorsaVi, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
dorsaVi0000N/A

Summary

dorsaVi beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Cryosite (ASX:CTE) and dorsaVi (ASX:DVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Cryosite and dorsaVi's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A

Cryosite has higher revenue and earnings than dorsaVi.

Profitability

This table compares Cryosite and dorsaVi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
dorsaViN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Cryosite and dorsaVi, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
dorsaVi0000N/A

Summary

Cryosite beats dorsaVi on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for dorsaVi and Epigenomics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
Epigenomics0000N/A

Earnings & Valuation

This table compares dorsaVi and Epigenomics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
EpigenomicsN/AN/AN/AN/AN/A

Epigenomics has lower revenue, but higher earnings than dorsaVi.

Profitability

This table compares dorsaVi and Epigenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
EpigenomicsN/AN/AN/A

Summary

dorsaVi beats Epigenomics on 1 of the 1 factors compared between the two stocks.


dorsaVi Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$12.39flat$0.00N/A0.00News Coverage
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00High Trading Volume
Gap Up
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$462.50flat$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00$4.95 million0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$29.28flat$0.00N/A0.00
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$19.88flat$0.00N/A0.00
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at co[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.